Nov 17, 2019: From subgroup analysis of the TWILIGHT trial in patients with non-ST elevation acute coronary syndromes(NSTE-ACS), Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT).
NSTE-ACS subgroup analysis shows results like As compared to ticagrelor plus aspirin (3.6% vs. 7.6%, HR 0.47; 95% CI: 0.36-0.61), results showed by Ticagrelor monotherapy was found to be 4.0% risk reduction in bleeding.
Likewise, Thrombolysis in Myocardial Infarction (TIMI) major bleeding at one year was found to be 0.5% for ticagrelor plus placebo and 1.0% for ticagrelor plus aspirin.
Also the death rates in one year are (1.0% for ticagrelor plus placebo and 1.5% for ticagrelor plus aspirin), MI (3.1% and 3.1%), ischemic stroke (0.5% and 0.3%), and definite or probable stent thrombosis (0.4% and 0.6%).
Rates of other secondary endpoints also were similar between the two groups at one year – all-cause death. As concluded, there was a lower risk of bleeding compared with standard 12 months of dual antiplatelet therapy with ticagrelor plus aspirin. https://www.astrazeneca.com/media-centre/medical-releases/subgroup-analysis-of-twilight-trial-patients-with-nste-acs.html